See more : Hoshizaki Corporation (HSHZY) Income Statement Analysis – Financial Results
Complete financial analysis of CTI BioPharma Corp. (CTIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CTI BioPharma Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vodacom Group Limited (VDMCY) Income Statement Analysis – Financial Results
- INTLOOP Inc. (9556.T) Income Statement Analysis – Financial Results
- Friendable, Inc. (FDBL) Income Statement Analysis – Financial Results
- Chiyoda Corporation (6366.T) Income Statement Analysis – Financial Results
- Nordic LEVEL Group AB (publ.) (LEVEL.ST) Income Statement Analysis – Financial Results
CTI BioPharma Corp. (CTIC)
About CTI BioPharma Corp.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.95M | 0.00 | 0.00 | 3.35M | 26.29M | 25.15M | 57.41M | 16.12M | 60.08M | 34.68M | 0.00 | 0.00 | 319.00K | 80.00K | 11.43M | 127.00K | 80.00K | 16.09M | 29.59M | 24.77M | 16.90M | 6.24M | 502.04K | 100.00K | 13.20M | 11.80M | 9.10M |
| Cost of Revenue | 3.51M | 161.00K | 4.20M | 0.00 | 879.00K | 364.00K | 1.38M | 1.94M | 895.00K | 137.00K | 0.00 | 0.00 | 0.00 | 0.00 | 3.24M | 49.00K | 0.00 | 518.00K | 1.10M | 840.00K | 423.00K | 394.00K | -1.02M | -2.20M | -1.90M | -1.60M | 14.30M |
| Gross Profit | 50.43M | -161.00K | -4.20M | 3.35M | 25.41M | 24.78M | 56.03M | 14.18M | 59.18M | 34.54M | 0.00 | 0.00 | 319.00K | 80.00K | 8.19M | 78.00K | 80.00K | 15.57M | 28.49M | 23.93M | 16.47M | 5.84M | 1.53M | 2.30M | 15.10M | 13.40M | -5.20M |
| Gross Profit Ratio | 93.49% | 0.00% | 0.00% | 100.00% | 96.66% | 98.55% | 97.60% | 87.96% | 98.51% | 99.60% | 0.00% | 0.00% | 100.00% | 100.00% | 71.62% | 61.42% | 100.00% | 96.78% | 96.27% | 96.61% | 97.50% | 93.68% | 304.14% | 2,300.00% | 114.39% | 113.56% | -57.14% |
| Research & Development | 36.90M | 39.14M | 25.94M | 24.11M | 36.47M | 32.87M | 64.96M | 76.63M | 86.46M | 33.62M | 62.31M | 34.90M | 27.03M | 30.18M | 51.61M | 72.02M | 61.99M | 68.77M | 101.13M | 89.53M | 58.76M | 44.67M | 26.57M | 27.70M | 29.20M | 27.30M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 17.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 84.83M | 56.20M | 17.63M | 19.16M | 21.18M | 31.44M | 45.31M | 53.96M | 56.24M | 42.29M | 38.24M | 38.29M | 48.04M | 57.73M | 41.61M | 35.32M | 35.30M | 61.72M | 78.52M | 55.64M | 49.80M | 35.27M | 20.42M | 9.80M | 11.60M | 10.10M | 7.60M |
| Other Expenses | 8.51M | -161.00K | 4.20M | 1.32M | 0.00 | 0.00 | -5.08M | 253.00K | 2.72M | 155.00K | 30.05M | 0.00 | 0.00 | 0.00 | -7.79M | 913.00K | 792.00K | -69.96M | 2.29M | 1.34M | 6.70M | 9.39M | 10.43M | 2.20M | 1.90M | 1.60M | 1.80M |
| Operating Expenses | 130.23M | 95.33M | 47.77M | 43.26M | 57.65M | 64.30M | 105.19M | 130.84M | 145.42M | 75.91M | 100.55M | 73.19M | 75.07M | 87.90M | 85.44M | 108.25M | 98.09M | 60.53M | 181.94M | 146.51M | 115.26M | 89.33M | 57.43M | 39.70M | 42.70M | 39.00M | 9.40M |
| Cost & Expenses | 133.75M | 95.33M | 47.77M | 43.26M | 58.53M | 64.67M | 106.57M | 132.78M | 146.31M | 76.05M | 100.55M | 73.19M | 75.07M | 87.90M | 88.68M | 108.30M | 98.09M | 61.05M | 183.05M | 147.35M | 115.68M | 89.72M | 56.40M | 37.50M | 40.80M | 37.40M | 23.70M |
| Interest Income | 1.68M | 38.00K | 204.00K | 1.17M | 1.22M | 0.00 | -2.61M | -2.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.14M | 2.42M | 1.03M | 1.52M | 1.73M | 2.04M | 2.83M | 2.49M | 2.68M | 1.54M | 56.00K | 1.04M | 2.33M | 4.81M | 8.56M | 14.83M | 44.58M | 17.56M | 10.99M | 9.33M | 11.24M | 5.99M | 544.29K | 0.00 | 400.00K | 0.00 | 500.00K |
| Depreciation & Amortization | -56.00K | -161.00K | 204.00K | 3.29M | 593.00K | 717.00K | 831.00K | 990.00K | 1.10M | 1.57M | 2.35M | 2.41M | 1.84M | 1.77M | 5.23M | 4.69M | 6.50M | 10.28M | 11.43M | 8.44M | 14.24M | 12.24M | 10.43M | 2.20M | 1.90M | 1.60M | 1.80M |
| EBITDA | -79.85M | -95.33M | -47.77M | -37.43M | -32.90M | -39.52M | -49.16M | -116.67M | -86.23M | -39.63M | -98.97M | -58.91M | -74.76M | -81.56M | -77.28M | -132.99M | -98.60M | -57.73M | -229.88M | -112.27M | -98.79M | -62.05M | -40.95M | -34.10M | -22.70M | -21.40M | -11.60M |
| EBITDA Ratio | -148.02% | 0.00% | 0.00% | -1,118.83% | -102.67% | -150.79% | -84.23% | -719.40% | -149.13% | -114.29% | 0.00% | 0.00% | -24,597.49% | -111,022.50% | -1,454.18% | -93,375.59% | -105,916.25% | -464.01% | -776.77% | -453.32% | -144.55% | -995.00% | -8,156.98% | -34,100.00% | -171.97% | -181.36% | -127.47% |
| Operating Income | -79.80M | -95.33M | -47.77M | -40.71M | -32.90M | -39.52M | -49.16M | -116.67M | -86.23M | -41.53M | -101.50M | -62.19M | -74.76M | -81.56M | -77.28M | -132.99M | -98.60M | -57.73M | -240.83M | -122.59M | -98.79M | -83.49M | -55.90M | -37.40M | -27.60M | -25.60M | -14.60M |
| Operating Income Ratio | -147.91% | 0.00% | 0.00% | -1,217.07% | -125.14% | -157.16% | -85.64% | -723.91% | -143.54% | -119.75% | 0.00% | 0.00% | -23,434.17% | -101,948.75% | -676.02% | -104,713.39% | -123,250.00% | -358.77% | -813.77% | -494.99% | -584.68% | -1,338.76% | -11,134.98% | -37,400.00% | -209.09% | -216.95% | -160.44% |
| Total Other Income/Expenses | -13.20M | -2.58M | -4.68M | 688.00K | 3.55M | -1.31M | -3.79M | -4.10M | -8.00M | -2.02M | -190.00K | -429.00K | -20.64M | -13.84M | -102.75M | -5.12M | -37.22M | -44.77M | -11.47M | -7.45M | 48.88M | 9.20M | 4.52M | 1.70M | 3.00M | 2.90M | 1.20M |
| Income Before Tax | -92.99M | -97.91M | -52.45M | -40.02M | -29.35M | -40.83M | -52.95M | -120.76M | -94.23M | -43.55M | -101.69M | -62.62M | -95.40M | -95.40M | -180.03M | -138.11M | -135.82M | -102.51M | -252.30M | -130.03M | -49.90M | -74.29M | -51.38M | -35.70M | -24.60M | -22.70M | -13.40M |
| Income Before Tax Ratio | -172.37% | 0.00% | 0.00% | -1,196.50% | -111.65% | -162.38% | -92.24% | -749.34% | -156.85% | -125.58% | 0.00% | 0.00% | -29,904.39% | -119,243.75% | -1,574.78% | -108,746.46% | -169,773.75% | -636.99% | -852.53% | -525.06% | -295.35% | -1,191.23% | -10,235.12% | -35,700.00% | -186.36% | -192.37% | -147.25% |
| Income Tax Expense | -1.95M | 1.73M | 500.00K | 2.29M | 5.28M | 723.00K | -963.00K | -1.60M | -5.32M | -485.00K | -134.00K | 609.00K | -3.41M | 1.79M | -85.79M | -362.00K | 51.35M | 48.78M | -76.87M | 11.21M | 71.36M | 15.19M | 5.06M | 1.70M | 3.40M | 2.90M | 1.70M |
| Net Income | -91.04M | -99.64M | -52.95M | -42.32M | -29.32M | -40.67M | -52.01M | -119.42M | -93.37M | -42.74M | -101.37M | -62.36M | -82.64M | -95.40M | -180.03M | -138.11M | -135.82M | -102.51M | -252.30M | -130.03M | -49.90M | -80.27M | -51.93M | -36.30M | -25.00M | -23.00M | -13.90M |
| Net Income Ratio | -168.76% | 0.00% | 0.00% | -1,265.08% | -111.53% | -161.74% | -90.60% | -741.02% | -155.41% | -123.26% | 0.00% | 0.00% | -25,906.58% | -119,243.75% | -1,574.78% | -108,746.46% | -169,773.75% | -636.99% | -852.53% | -525.06% | -295.35% | -1,287.25% | -10,343.54% | -36,300.00% | -189.39% | -194.92% | -152.75% |
| EPS | -0.79 | -1.11 | -0.74 | -0.73 | -0.52 | -1.12 | -1.86 | -4.26 | -6.29 | -3.74 | -17.44 | -18.18 | -36.21 | -62.44 | -1.86K | -9.15K | -14.52K | -19.06K | -56.02K | -46.71K | -17.74K | -28.49K | -24.59K | -28.03K | -19.47K | -17.95K | -12.81K |
| EPS Diluted | -0.79 | -1.11 | -0.74 | -0.73 | -0.52 | -1.12 | -1.86 | -4.26 | -6.29 | -3.74 | -17.44 | -18.18 | -36.21 | -62.44 | -1.86K | -9.15K | -14.52K | -19.06K | -56.02K | -46.71K | -17.74K | -28.49K | -24.59K | -28.03K | -19.47K | -17.95K | -12.81K |
| Weighted Avg Shares Out | 114.69M | 90.12M | 71.14M | 57.97M | 56.07M | 36.45M | 27.95M | 28.05M | 14.85M | 11.42M | 5.81M | 3.43M | 2.28M | 1.53M | 96.56K | 15.10K | 9.36K | 5.38K | 4.50K | 2.78K | 2.81K | 2.82K | 2.11K | 1.30K | 1.28K | 1.28K | 1.09K |
| Weighted Avg Shares Out (Dil) | 114.69M | 90.12M | 71.14M | 57.97M | 56.07M | 36.45M | 27.95M | 28.05M | 14.85M | 11.42M | 5.81M | 3.43M | 2.28M | 1.53M | 96.56K | 15.10K | 9.36K | 5.38K | 4.50K | 2.78K | 2.81K | 2.82K | 2.11K | 1.30K | 1.28K | 1.28K | 1.09K |
CTI BioPharma to Present at Upcoming June Conferences
SEATTLE , June 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York City. Presentation details: Event: Jefferies Healthcare ConferenceDate: Friday, June 10, 2022...
CTI BioPharma Presents Pivotal Data from Pacritinib Program at the 2022 American Society of Clinical Oncology Annual Meeting
SEATTLE , May 26, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced a poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago and virtually, June...
Why CTI Biopharma Stock Is Surging Today
A strong launch for the company's first commercialized drug drew a cheer from investors.
CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q1 2022 Results - Earnings Call Transcript
CTI BioPharma Corp. (NASDAQ:CTIC ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Adam Craig - CEO and President of CTI BioPharma James Fong - SVP and Chief Commercial Officer David Kirske - EVP, CFO...
CTI BioPharma Reports First Quarter 2022 Financial Results
– Strong U.S. commercial launch of VONJO™ (pacritinib) underway following accelerated FDA approval for the treatment of adult patients with Myelofibrosis and Thrombocytopenia – – VONJO (pacritinib) net product revenue of $2.3 million in less than one month following launch,...
CTI BioPharma Announces Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
SEATTLE , May 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced one poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago and virtually, June...
CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset
CTIC is undervalued and a strong buy for new investors. The current share price of ~$5.63 does not reflect the potential of outsized returns to patient, long-term investors. Under conservative assumptions, my DCF model shows the equity value of CTIC...
NCCN Guidelines® Recommend VONJO™ (pacritinib) for the Treatment of Myeloproliferative Neoplasms
VONJO is the only approved JAK inhibitor recommended by NCCN for myelofibrosis patients regardless of platelet count SEATTLE , April 14, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that VONJO™ (pacritinib), its novel oral kinase inhibitor with specificity...
CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -35.71% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results
– VONJOTM (pacritinib) Approved by FDA for the Treatment of Adult Myelofibrosis Patients with Myelofibrosis and Thrombocytopenia; Commercial Launch Underway – – $60 Million Payment from DRI Healthcare Trust Triggered by FDA Approval under the Terms of the Previously Announced...
Source: https://incomestatements.info
Category: Stock Reports